Propranolol-d7

Propranolol-d7

• CAS Number: 98897-23-5
• UNSPSC Description: Propranolol-d7 is the deuterium labeled Propranolol. Propranolol is a nonselective β-adrenergic receptor (βAR) antagonist, has high affinity for the β1AR and β2AR with Ki values of 1.8 nM and 0.8 nM, respectively[1]. Propranolol inhibits [3H]-DHA binding to rat brain membrane preparation with an IC50 of 12 nM[2]. Propranolol is used for the study of hypertension, pheochromocytoma, myocardial infarction, cardiac arrhythmias, angina pectoris, and hypertrophic cardiomyopathy[3].
• Target Antigen: Adrenergic Receptor
• Type: Isotope-Labeled Compounds
• Related Pathways: GPCR/G Protein;Neuronal Signaling
• Field of Research: Neurological Disease; Cardiovascular Disease; Endocrinology
• Purity: 99.0
• Solubility: DMSO : 100 mg/mL (ultrasonic)
• Smiles: OC(COC1=C2C=CC=CC2=CC=C1)CNC([2H])(C([2H])([2H])[2H])C([2H])([2H])[2H]
• Molecular Weight: 266.39
• References & Citations: [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. |[2]Galandrin S, et al. Distinct signaling profiles of beta1 and beta2 adrenergic receptor ligands toward adenylyl cyclase and mitogen-activated protein kinase reveals the pluridimensionality of efficacy. Mol Pharmacol. 2006 Nov;70(5):1575-84. Epub 2006 Aug 1|[3]Briley M, et al. Evidence against beta-adrenoceptor blocking activity of diltiazem, a drug with calcium antagonist properties. Br J Pharmacol. 1980 Aug;69(4):669-73.|[4]Al-Majed AA, et al. Propranolol. Profiles Drug Subst Excip Relat Methodol. 2017;42:287-338.|[5]Munabi NC, et al. Propranolol Targets Hemangioma Stem Cells via cAMP and Mitogen-Activated Protein Kinase Regulation. Stem Cells Transl Med. 2016 Jan;5(1):45-55.
• Shipping Conditions: Blue Ice
• Storage Conditions: -20°C, 3 years (Powder)
• Clinical Information: No Development Reported